CSPC Innovation Pharmaceutical Co., Ltd. (300765.SZ)
CNY 41.91
(5.83%)
CNY 41.91
(5.83%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 511.7 Million CNY | -20.03% |
| 2022 | 639.84 Million CNY | 141.05% |
| 2021 | 265.43 Million CNY | -0.96% |
| 2020 | 268 Million CNY | -38.68% |
| 2019 | 437.06 Million CNY | 11.65% |
| 2018 | 391.45 Million CNY | 8.09% |
| 2017 | 362.16 Million CNY | -8.7% |
| 2016 | 396.66 Million CNY | 20.13% |
| 2015 | 330.19 Million CNY | 12.06% |
| 2014 | 294.65 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 970.19 Million CNY | 10.59% |
| 2024 Q1 | 989.33 Million CNY | 93.34% |
| 2024 Q2 | 877.3 Million CNY | -11.32% |
| 2023 Q1 | 566.56 Million CNY | -11.45% |
| 2023 FY | 511.7 Million CNY | -20.03% |
| 2023 Q4 | 511.7 Million CNY | 10.18% |
| 2023 Q3 | 464.43 Million CNY | -13.9% |
| 2023 Q2 | 539.41 Million CNY | -4.79% |
| 2022 Q3 | 327.12 Million CNY | 12.52% |
| 2022 FY | 639.84 Million CNY | 141.05% |
| 2022 Q4 | 639.84 Million CNY | 95.6% |
| 2022 Q1 | 278.68 Million CNY | 4.99% |
| 2022 Q2 | 290.73 Million CNY | 4.32% |
| 2021 Q1 | 287.67 Million CNY | 7.34% |
| 2021 Q4 | 265.43 Million CNY | 11.09% |
| 2021 FY | 265.43 Million CNY | -0.96% |
| 2021 Q2 | 251.39 Million CNY | -12.61% |
| 2021 Q3 | 238.94 Million CNY | -4.96% |
| 2020 FY | 268 Million CNY | -38.68% |
| 2020 Q1 | 429.42 Million CNY | -1.75% |
| 2020 Q2 | 351.47 Million CNY | -18.15% |
| 2020 Q3 | 304.39 Million CNY | -13.39% |
| 2020 Q4 | 268 Million CNY | -11.96% |
| 2019 Q4 | 437.06 Million CNY | 39.0% |
| 2019 FY | 437.06 Million CNY | 11.65% |
| 2019 Q2 | 376.36 Million CNY | -2.55% |
| 2019 Q1 | 386.23 Million CNY | -1.33% |
| 2019 Q3 | 314.43 Million CNY | -16.46% |
| 2018 Q1 | - CNY | -100.0% |
| 2018 Q4 | 391.45 Million CNY | 0.0% |
| 2018 Q2 | 411.98 Million CNY | 0.0% |
| 2018 FY | 391.45 Million CNY | 8.09% |
| 2017 Q4 | 362.16 Million CNY | 0.0% |
| 2017 FY | 362.16 Million CNY | -8.7% |
| 2017 Q1 | 288.88 Million CNY | 0.0% |
| 2017 Q2 | 326.95 Million CNY | 13.18% |
| 2017 Q3 | 362.16 Million CNY | 10.77% |
| 2016 FY | 396.66 Million CNY | 20.13% |
| 2015 FY | 330.19 Million CNY | 12.06% |
| 2014 FY | 294.65 Million CNY | 0.0% |